Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An bleeding disorder with a decreased antigen and/or activity of factor X (FX) that is acquired. Acquired factor X deficiency is a rare disorder, commonly associated with a preceding viral illness and a circulating FX inhibitor. Although multiple treatment modalities have been described with variable success, in many cases, it is a self-limited condition.
No approved treatments are currently available for acquired factor X deficiency. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for acquired factor X deficiency, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for acquired factor X deficiency. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
1 clinical trial registered, 1 recruiting. Interventions under study include biologic therapy. Pipeline includes 1 PHASE3. Research is primarily industry-sponsored.
5 publications have been identified in PubMed for acquired factor X deficiency. Research spans Review / Meta-Analysis (40%), Case Report / Case Series (40%), and Other (20%).
Cetin O (2025). [PMID: 40981270](https://pubmed.ncbi.nlm.nih.gov/40981270/). *Am J Hematol*. [Other]
Ross A (2025). [PMID: 40126219](https://pubmed.ncbi.nlm.nih.gov/40126219/). *Hematol Rep*. [Case Report / Case Series]
Iglay K (2025). [PMID: 40151020](https://pubmed.ncbi.nlm.nih.gov/40151020/). *Hematology*. [Review / Meta-Analysis]
Liu KS (2025). [PMID: 40692818](https://pubmed.ncbi.nlm.nih.gov/40692818/). *Gastro Hep Adv*. [Case Report / Case Series]
Zhang J (2024). [PMID: 40032332](https://pubmed.ncbi.nlm.nih.gov/40032332/). *Zhonghua Xue Ye Xue Za Zhi*. [Review / Meta-Analysis]
Data assembled from 5 of 12 sources · Last updated Oct 3, 2026, 8:02 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about acquired factor X deficiency
Designated
Exclusivity End |
|---|
Designation Status |
|---|
Coagulation Factor X Human | Coagulation Factor X Human | Bio Products Laboratory Limited | 2023 | — | Designated |
1 trial found